Janusitin Tablet 25mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Korea Pavis Pharmaceutical Co., Ltd.
MFDS item code 202004057 · Approved 2020.05.29
This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with type 2 diabetes. It may be administered alone as an adjunct to dietary and exercise therapy. If there has been no prior experience with diabetes medication and blood sugar control is difficult with monotherapy, it should be used in combination with metformin. Additionally, this drug helps effectively manage blood sugar when sufficient control is not achievable with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin. It is also used reliably to improve blood sugar control in situations requiring combination therapy.
For monotherapy or combination therapy, administer 100mg once daily; the maximum daily dose is 100mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60mL/min/1.73m2 and < 90mL/min/1.73m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥45mL/min/1.73m2 and < 60mL/min/1.73m2). 3. Administer 50mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥30mL/min/1.73m2 and < 45mL/min/1.73m2). 4. Administer 25mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥15mL/min/1.73m2 and < 30mL/min/1.73m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15mL/min/1.73m2). This medicine may be administered regardless of the timing of dialysis.
This medication can occasionally cause serious allergic reactions; therefore, if symptoms such as skin rash or difficulty breathing occur, the medication should be stopped immediately and a doctor should be consulted. There is also a risk of acute pancreatitis, which is inflammation of the pancreas; thus, if symptoms such as abdominal pain, vomiting, or loss of appetite appear during treatment, medical consultation should be sought immediately. This drug should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in cases of hypersensitivity to the drug or its components. Patients with impaired renal function may require dosage adjustments due to slower excretion of the drug, and regular kidney function evaluations before and during treatment are important. Hypoglycemic symptoms may occur when using this drug, especially when combined with insulin or sulfonylurea, so blood sugar levels should be monitored closely and dosage adjustments may be necessary for those medications. If severe joint pain or blistering of the skin occurs, consult a physician immediately, and the medication may need to be discontinued in such cases. Use in pregnant or breastfeeding women is not recommended, and safety and efficacy have not been established in children under 18 years old. Elderly patients should use this drug with caution due to the potential for impaired renal function, and regular kidney function tests are required. In case of overdose, general treatment should be implemented, including removal of the drug from the gastrointestinal tract and monitoring of electrocardiograms, and some drugs may be removed via hemodialysis. This medication may interact with other diabetes treatments or certain medications, so it is important to inform your doctor or pharmacist of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container, preferably at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its effectiveness.
Light orange, round, bilaterally convex film-coated tablet
28 tablets/box [(14 tablets/PVC*2)], 30 tablets/box [(10 tablets/PVC*3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Korea Pavis Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.